Delapril hydrochloride
(Synonyms: 地拉普利盐酸盐) 目录号 : GC38766
Delapril Hydrochloride (Alindapril) is the hydrochloride salt form of delapril, which is a lipophilic, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity.
Cas No.:83435-67-0
Sample solution is provided at 25 µL, 10mM.
Delapril Hydrochloride (Alindapril) is the hydrochloride salt form of delapril, which is a lipophilic, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity.
The poteny of delapril is about 15 times greater than captopril and almost equal to enalaprilat in inhibiting rabbit lung ACE activity in vitro and about 10 times greater than captopril in inhibiting angiotensin I-induced contraction in isolated tissue preparations, such as rat aortic rings and rat kidney[2].
After oral administration of [14C]delapril 10 mg/kg to rats, 57% of the dose is absorbed mainly in the small intestine via the portal route and extensively metabolized by esterases to the diacid derivative M-I. Plasma levels of M-I peak within 0.4 hour of administration (maximum concentration [Cmax] 1.23 μg/mL), then decline biphasically with half-lives of 0.6 and 9.1 hours. In dogs given 10 mg/kg of [14C]delapril, 72% of the dose is absorbed. Plasma levels of M-I peak within 0.4 hour of administration (Cmax, 0.9 μg/ mL), then decline biphasically with half-lives of 0.3 and 2.8 hours. Delapril is able to inhibit plasma and tissue ACE at doses 5-10 times lower than captopril and this has also been found in in vivo experiments. Delapril has been shown to decrease heart weight, left ventricular weight, the wall to lumen ratio of small coronary arterioles, and thickness of the left ventricular wall in stroke-prone SHR, to reduce cardiac renin gene expression in SHR, and to protect perfused rat hearts against ischemia-reperfusion injury[2].
[1] Saruta T, et al. Am J Hypertens. 1991, 4(1 Pt 2):23S-28S. [2] Razzetti R, et al. Am J Cardiol. 1995, 75(18):7F-12F.
Cas No. | 83435-67-0 | SDF | |
别名 | 地拉普利盐酸盐 | ||
Canonical SMILES | CCOC([C@H](CCC1=CC=CC=C1)N[C@@H](C)C(N(C2CC3=C(C=CC=C3)C2)CC(O)=O)=O)=O.[H]Cl | ||
分子式 | C26H33ClN2O5 | 分子量 | 489 |
溶解度 | DMSO: 250 mg/mL (511.25 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.045 mL | 10.2249 mL | 20.4499 mL |
5 mM | 0.409 mL | 2.045 mL | 4.09 mL |
10 mM | 0.2045 mL | 1.0225 mL | 2.045 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet